(Q73280044)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12699304%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

review article

1 reference

title

New anabolic therapies in osteoporosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12699304%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

John P Bilezikian

1 reference

2 November 2019

Mishaela R Rubin

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12699304%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

publication date

1 March 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12699304%20AND%20SRC:MED&resulttype=core&format=json

Endocrinology and Metabolism Clinics of North America

2 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12699304%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12699304%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12699304%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

page(s)

285-307

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12699304%20AND%20SRC:MED&resulttype=core&format=json

Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial

2 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Safe and effective treatment of osteoporosis with intermittent slow release sodium fluoride: augmentation of vertebral bone mass and inhibition of fractures

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Treatment of Postmenopausal Osteoporosis with Slow-Release Sodium Fluoride: Final Report of a Randomized Controlled Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Slow-release sodium fluoride in osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Clinical trial of fluoride therapy in postmenopausal osteoporotic women: extended observations and additional analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Therapy of established postmenopausal osteoporosis with monofluorophosphate plus calcium: dose-related effects on bone density and fracture rate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Avoidance of vertebral fractures in men with idiopathic osteoporosis by a three year therapy with calcium and low-dose intermittent monofluorophosphate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Treatment of osteoporosis in men with fluoride alone or in combination with bisphosphonates

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Insulin-like growth factors and bone: the osteoporosis connection revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Serum Levels of Insulin-like Growth Factor (IGF) I, IGF-Binding Protein (IGFBP)-2, and IGFBP-3 in Osteoporotic Patients with and without Spinal Fractures

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Effects of human growth hormone in men over 60 years old

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Effects of recombinant insulin-like growth factor-I and growth hormone on bone turnover in elderly women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

The incorporation and removal of large amounts of strontium by physiologic mechanisms in mineralized tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Strontium induces murine keratinocyte differentiation in vitro in the presence of serum and calcium

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Cation Sensing Receptors in Bone: A Novel Paradigm for Regulating Bone Remodeling?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Extracellular calcium sensing and extracellular calcium signaling

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Effects of strontium on calcium metabolism in rats. I. A distinction between the pharmacological and toxic doses.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis--a 2-year randomized placebo controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

The prevention of osteoporosis using sequential low-dose hormone replacement therapy with estradiol-17 beta and dydrogesterone

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Oral statins and increased bone-mineral density in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

HMG-CoA reductase inhibitors and the risk of fractures

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Statin Use, Bone Mineral Density, and Fracture Risk

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Stimulation of bone formation in vitro and in rodents by statins

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Use of statins and risk of fractures

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: a two-year randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

The response in spinal bone mass to tibolone treatment is related to bone turnover in elderly women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Prospective double-blind trial of synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Non-linear increase in vertebral density induced by a synthetic steroid (Org OD 14) in women with established osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Short-term effects of Org OD 14 and 17 beta-oestradiol on bone and lipid metabolism in early post-menopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Tibolone: a steroid with a tissue-specific mode of action

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Postmenopausal osteoporosis management

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Anabolic effects of parathyroid hormone on bone

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Parathyroid hormone causes translocation of protein kinase-C from cytosol to membranes in rat osteosarcoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Interactions of PTH and PTHrP with the PTH/PTHrP receptor and with downstream signaling pathways: exceptions that provide the rules

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Human parathyroid hormone-(1-34) increases bone mass in ovariectomized and orchidectomized rats

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Parathyroid hormone stimulates release of insulin-like growth factor-I (IGF-I) and IGF-II from neonatal mouse calvaria in organ culture

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Parathyroid hormone restores bone mass and enhances osteoblast insulin-like growth factor I gene expression in ovariectomized rats

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Response of cortical bone to antiresorptive agents and parathyroid hormone in aged ovariectomized rats

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Cyclical treatment of osteopenic ovariectomized adult rats with PTH(1-34) and pamidronate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Bone tissue and its mineralization in aged estrogen-depleted rats after long-term intermittent treatment with parathyroid hormone (PTH) analog SDZ PTS 893 or human PTH(1-34).

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Reduced serum levels of the growth hormone-dependent insulin-like growth factor binding protein and a negative bone balance at the level of individual remodeling units in idiopathic osteoporosis in men.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Prediction of bone mass change after parathyroidectomy in patients with primary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Primary hyperparathyroidism: changes in trabecular bone remodeling following surgical treatment--evaluated by histomorphometric methods

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

Molecular cloning and functional expression of human parathyroid calcium receptor cDNAs

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900056-7

7 January 2021

10.1016/S0889-8529(02)00056-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12699304%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12699304%20AND%20SRC:MED&resulttype=core&format=json